{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:59:05Z","timestamp":1772121545875,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T00:00:00Z","timestamp":1716076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.prp.2024.155352","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:54:06Z","timestamp":1715954046000},"page":"155352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The clinicopathological features and possible physiological mechanisms of only the EGFR-T790M primary mutation in patients with lung adenocarcinoma"],"prefix":"10.1016","volume":"259","author":[{"given":"Ping","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2024.155352_bib1","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.prp.2024.155352_bib2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non\u2013small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.prp.2024.155352_bib3","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA: A Cancer J. Clin."},{"key":"10.1016\/j.prp.2024.155352_bib4","doi-asserted-by":"crossref","unstructured":"J.S.-K.A. Yuankai Shi, Sumitra Thongprasert, Sankar Srinivasan, Chun-Ming Tsai, Mai Trong Khoa, Karin Heeroma, Yohji Itoh, Gerardo Cornelio, Pan-Chyr Yang, A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER), J Thorac Oncol 9\uff082\uff09 (2014) 154-162. https:\/\/doi: 10.1097\/JTO.0000000000000033.","DOI":"10.1097\/JTO.0000000000000033"},{"key":"10.1016\/j.prp.2024.155352_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13010016","article-title":"Predicting tumor mutation burden and EGFR mutation using clinical and radiomic features in patients with malignant pulmonary nodules","volume":"13","author":"Yin","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.prp.2024.155352_bib6","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.2147\/CMAR.S323972","article-title":"Different clinicopathologic and computed tomography imaging characteristics of primary and acquired EGFR T790M mutations in patients with non-small-cell lung cancer","volume":"Volume 13","author":"Hou","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.prp.2024.155352_bib7","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1002\/ijc.32015","article-title":"Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation","volume":"144","author":"Wang","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2024.155352_bib8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.prp.2024.155352_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051445","article-title":"Favorable conditions for the detection of EGFR T790M mutation using plasma sample in patients with non-small-cell lung cancer","volume":"15","author":"Kim","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155352_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107438","article-title":"Drug resistance to targeted therapeutic strategies in non-small cell lung cancer","volume":"206","author":"Liu","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.prp.2024.155352_bib11","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1158\/0008-5472.CAN-16-2359","article-title":"Amplification of EGFR Wild-type alleles in non\u2013small cell lung cancer cells confers acquired resistance to mutation-selective egfr tyrosine kinase inhibitors","volume":"77","author":"Nukaga","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2024.155352_bib12","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.prp.2024.155352_bib13","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.21037\/tlcr-23-160","article-title":"Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer","volume":"12","author":"Park","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.prp.2024.155352_bib14","doi-asserted-by":"crossref","DOI":"10.1186\/s13019-022-02071-7","article-title":"Osimertinib showed efficacy on contralateral multiple ground-glass nodules after segmentectomy for lung adenocarcinoma harboring primary EGFR-T790M mutation: a case report and review of the literature","volume":"17","author":"Dong","year":"2022","journal-title":"J. Cardiothorac. Surg."},{"key":"10.1016\/j.prp.2024.155352_bib15","doi-asserted-by":"crossref","unstructured":"D.R.S. Leora Horn, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, E.F. Hossein Borghaei, Luis Paz-Ares, Adam Pluzanski, Karen L. Reckamp, Marco A. Burgio, Martin, D.W. Kohlhaeu \u00a8 fl, Fabrice Barlesi, Scott Antonia, Oscar Arrieta, J\u00b4erome Fayette, Lucio Crin \u02c6 o, Naiyer `, M.R. Rizvi, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood-Chirchir, Diane Healey, a.W.E.E.E. Julie Brahmer, Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non\u2013Small-Cell Lung Cancer Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057), Journal of clinical oncology 35 (2017) 3924-3933. https:\/\/doi: 10.1200\/JCO.2017.74.3062.","DOI":"10.1200\/JCO.2017.74.3062"},{"key":"10.1016\/j.prp.2024.155352_bib16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2024.155352_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-017-0591-1","article-title":"CD73\/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer","volume":"16","author":"Zhu","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2024.155352_bib18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jtho.2020.12.010","article-title":"Characterization of the immune landscape of EGFR-Mutant NSCLC identifies CD73\/adenosine pathway as a potential therapeutic target","volume":"16","author":"Le","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2024.155352_bib19","unstructured":"M.D.E.W. David S. Ettinger, MD, FRCSEd, Dara L. Aisner, MD, PhD; Wallace Akerley, MD, Jessica Bauman, MD; Lucian R. Chirieac, MD, Thomas A. D\u2019Amico, MD; Malcolm M. DeCamp, MD, Thomas J. Dilling, MD, MS; Michael Dobelbower, MD, PhD, Robert C. Doebele, MD, PhD; Ramaswamy Govindan, MD, Matthew A. Gubens, MD, MS; Mark Hennon, MD, Leora Horn, MD, MSc, FRCPC; Ritsuko Komaki, MD;, Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(4) (2017) 504-535. https:\/\/d oi: 10.6004\/jnccn.2017.0050."},{"issue":"9","key":"10.1016\/j.prp.2024.155352_bib20","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1373\/clinchem.2017.271932","article-title":"Reducing artifactual EGFR T790M mutations in DNA from formalin-fixed paraffin-embedded tissue by use of thymine-DNA glycosylase","volume":"63","author":"Do","year":"2017","journal-title":"Clin. Chem."},{"key":"10.1016\/j.prp.2024.155352_bib21","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1111\/1759-7714.13702","article-title":"Prognostic impact of micropapillary component in patients with node-negative subcentimeter lung adenocarcinoma: a Chinese cohort study","volume":"11","author":"Yao","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.prp.2024.155352_bib22","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1245\/s10434-015-5043-9","article-title":"Minor components of micropapillary and solid subtypes in lung adenocarcinoma are predictors of lymph node metastasis and poor prognosis","volume":"23","author":"Zhao","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.prp.2024.155352_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ejcts\/ezv058","article-title":"Negative prognostic influence of micropapillary pattern in stage IA lung adenocarcinoma","volume":"49","author":"Tsubokawa","year":"2016","journal-title":"Eur. J. Cardio-Thorac. Surg."},{"key":"10.1016\/j.prp.2024.155352_bib24","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1309\/AJCPBS85VJEOBPDO","article-title":"Micropapillary lung adenocarcinoma","volume":"131","author":"De Oliveira Duarte Achcar","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.prp.2024.155352_bib25","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jtcvs.2017.09.143","article-title":"Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma","volume":"155","author":"Qian","year":"2018","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.prp.2024.155352_bib26","article-title":"Prognostic value of CYFRA 21\u2009\u2212\u20091 and Ki67 in advanced NSCLC patients with wild-type EGFR","volume":"23","author":"Li","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2024.155352_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.10.005","article-title":"Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: a retrospective analysis","volume":"124","author":"Wang","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2024.155352_bib28","doi-asserted-by":"crossref","first-page":"967","DOI":"10.21037\/tlcr.2019.12.02","article-title":"Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers","volume":"8","author":"Ni","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2024.155352_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/2049-6958-7-29","article-title":"Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer","volume":"7","author":"Ciancio","year":"2012","journal-title":"Multidiscip. Respir. Med."},{"key":"10.1016\/j.prp.2024.155352_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137213","article-title":"The therapeutic potential of the restoration of the p53 protein family members in the EGFR-mutated lung cancer","volume":"23","author":"Fregni","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155352_bib31","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/leu.2016.282","article-title":"Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy","volume":"31","author":"Uy","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2024.155352_bib32","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-021-02396-8","article-title":"p53 signaling in cancer progression and therapy","volume":"21","author":"Marei","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.prp.2024.155352_bib33","article-title":"The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy","volume":"10","author":"Titmarsh","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2024.155352_bib34","doi-asserted-by":"crossref","DOI":"10.4103\/1477-3163.100401","article-title":"CyclinD1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-MB231 cells","volume":"11","author":"Luo","year":"2012","journal-title":"J. Carcinog."},{"issue":"8","key":"10.1016\/j.prp.2024.155352_bib35","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2217\/fon.15.15","article-title":"Common EGFR-mutated subgroups (Del19\/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors","volume":"11","author":"Reguart","year":"2015","journal-title":"Future Oncol."},{"key":"10.1016\/j.prp.2024.155352_bib36","article-title":"Correlation analysis between t790m status and clinical characteristics of patients with EGFR-sensitive mutation advanced NSCLC who progressed after the first-line EGFR-TKIs administration: a real-world exploratory study","author":"Liu","year":"2023","journal-title":"Comb. Chem. High. Throughput Screen. 26"},{"key":"10.1016\/j.prp.2024.155352_bib37","article-title":"Feiyiliu Mixture sensitizes EGFRDel19\/T790M\/C797S mutant non-small cell lung cancer to osimertinib by attenuating the PRC1\/Wnt\/EGFR pathway","volume":"14","author":"Shi","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.prp.2024.155352_bib38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non\u2013small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.prp.2024.155352_bib39","article-title":"Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors","volume":"2","author":"Du","year":"2021","journal-title":"Innovation"},{"key":"10.1016\/j.prp.2024.155352_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113417","article-title":"Inhibiting G6PD by quercetin promotes degradation of EGFR T790M mutation","volume":"42","author":"Ge","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.prp.2024.155352_bib41","doi-asserted-by":"crossref","first-page":"14481","DOI":"10.1002\/anie.202003500","article-title":"Mutant-selective allosteric EGFR degraders are effective against a broad range of drug-resistant mutations","volume":"59","author":"Jang","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.prp.2024.155352_bib42","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1080\/14756366.2022.2062338","article-title":"Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFRWT and EGFRT790M","volume":"37","author":"O. Aboelez","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.prp.2024.155352_bib43","article-title":"Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2024.155352_bib44","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.3892\/ol.2017.6022","article-title":"Dynamic monitoring of EGFR mutations in circulating cell-free DNA for EGFR-mutant metastatic patients with lung cancer: Early detection of drug resistance and prognostic significance","volume":"13","author":"Ni","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.prp.2024.155352_bib45","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-023-02609-y","article-title":"Application value of CT radiomic nomogram in predicting T790M mutation of lung adenocarcinoma","volume":"23","author":"Li","year":"2023","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.prp.2024.155352_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174231","article-title":"Monitoring of plasma EGFR mutations during osimertinib treatment for NSCLC patients with acquired T790M Mutation","volume":"15","author":"Watanabe","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155352_bib47","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy425.022","article-title":"AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS)","volume":"29","author":"Zhou","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2024.155352_bib48","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib Versus Crizotinib in ALK inhibitor\u2013naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L Trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2024.155352_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100527","article-title":"Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-na\u00efve Japanese patients with ALK-positive non-small-cell lung cancer","volume":"7","author":"Hotta","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.prp.2024.155352_bib50","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.annonc.2023.02.012","article-title":"Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial","volume":"34","author":"Remon","year":"2023","journal-title":"Ann. Oncol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824002632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824002632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T21:41:31Z","timestamp":1718228491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824002632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":50,"alternative-id":["S0344033824002632"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155352","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3876301\/v1","asserted-by":"object"}]},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinicopathological features and possible physiological mechanisms of only the EGFR-T790M primary mutation in patients with lung adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"155352"}}